(Reuters) - Novo Nordisk said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, citing manufacturing constraints, reduced patient access and available ...

After she was diagnosed at age 48 with Type 1 diabetes, Stacey Silverman muddled through her days with high blood sugar, fatigue and splitting headaches. Taking a long-acting form of insulin called ...

Levemir, one of the three types of long-acting basal insulins, is evacuating the U.S. market, and diabetes patient advocates told USA Today they’re worried about using a new medication after nearly ...

As a special education teacher living with Type 1 diabetes in Crawfordsville, I’ve relied on insulin to manage my condition since my diagnosis in 2011. Despite my engagement as an #insulin4all ...

A year ago today, Novo Nordisk announced significant list price reductions on its insulin medications. Unlike co-payment caps or discount cards, these were real cuts in the actual cost to patients and ...

Senators are demanding to know why Novo Nordisk discontinued Levemir, one of the nation’s three long-acting insulins. In an April 16 letter, New Hampshire Sen. Jeanne Shaheen, Georgia Sen. Raphael ...

Novo Nordisk (NVO) is reportedly set to meet with U.S. Senate aides on Tuesday to discuss why the drugmaker is discontinuing marketing its long-acting insulin Levemir in the U.S. The Danish drugmaker ...

A year ago, when Novo Nordisk announced it would cut the price of multiple insulin products by up to 75%, President Biden, lawmakers, and patient groups all counted the move as a win. But several ...

LONDON (Reuters) - Patients with type 2 diabetes are less likely to reach target blood sugar levels on Novo Nordisk's long-lasting insulin Levemir than on shorter-acting products, researchers said on ...

COPENHAGEN, Oct 22 (Reuters) - Denmark's Novo Nordisk , the world's biggest maker of insulin, said on Monday Japanese health authorities have approved it long-acting insulin Levemir for use in type 1 ...